#ES­MO22: Am­gen spot­lights con­fir­ma­to­ry win for KRAS G12C play­er Lumakras in lung can­cer — but there's plen­ty more da­ta to come

PARIS — Am­gen came to Paris with a two-step plan to re­veal con­fir­ma­to­ry Code­Break 200 tri­al da­ta for its KRAS G12C drug Lumakras in non-small cell lung can­cer. Af­ter tip­ping its cards ahead of the con­fer­ence to stake a top-line claim — sans da­ta — on hit­ting the pri­ma­ry end­point for me­di­an pro­gres­sion-free sur­vival over do­c­etax­el at 12 months, we’re get­ting the ini­tial snap­shot that de­tails just how the com­par­i­son stacks up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER